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Structure-activity relationshipsSmall-molecule inhibitors of urea transporter (UT) proteins in kidney have potential application as novel salt-
sparing diuretics. The urea analog dimethylthiourea (DMTU) was recently found to inhibit the UT isoforms
UT-A1 (expressed in kidney tubule epithelium) and UT-B (expressed in kidney vasa recta endothelium) with
IC50 of 2-3 mM, and was shown to have diuretic action when administered to rats. Here, we measured UT-A1
and UT-B inhibition activity of 36 thiourea analogs, with the goal of identifying more potent and isoform-
selective inhibitors, and establishing structure-activity relationships. The analog set systematically explored
modiﬁcations of substituents on the thiourea including alkyl, heterocycles and phenyl rings, with different steric
and electronic features. The analogs had a wide range of inhibition activities and selectivities. The most potent
inhibitor, 3-nitrophenyl-thiourea, had an IC50 of ~0.2 mM for inhibition of both UT-A1 and UT-B. Some analogs
such as 4-nitrophenyl-thiourea were relatively UT-A1 selective (IC50 1.3 vs. 10 mM), and others such as
thioisonicotinamide were UT-B selective (IC50 N 15 vs. 2.8 mM).
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Urea transporter (UT) proteins facilitate the passive transport of
urea across cell plasma membranes [1–4]. UTs are expressed mainly in
kidney, where they are required for the formation of a concentrated
urine by countercurrent multiplication and exchange mechanisms [2,
5,6]. UT-A isoforms encoded by the SLc14A2 gene are expressed in
kidney tubule epithelial cells and UT-B encoded by the SLc14A1 gene
is expressed in kidney vasa recta endothelial cells [7,8]. X-ray crystal
structures have been solved for a bacterial UT homolog produced by
Desulfovibrio vulgaris [9] and for bovine UT-B [10]. Studies in UT knock-
out mice [11–15] and in rodents administered UT inhibitors [16–18]
support the conclusion that UT-A1, the UT isoform expressed at the
luminal membrane of tubule epithelial cells in inner medullary
collecting duct, is the primary target for diuretic development.
Small-molecule screening from our laboratory has identiﬁed inhibi-
tors of UT-A1 and UT-B with a wide range of selectivities [16,19,20],
which are being characterized and optimized as potential drug candi-
dates. Interestingly, the small urea analog dimethylthiourea (DMTU),
which has been administered at high doses in experimental animallthiourea; MDCK, Madin-Darby
Tower, University of California,
0; fax +1 415 665 3847.
n).models as a hydroxyl radical scavenger [21,22], inhibits both UT-A1
andUT-B (IC50 2-3mM) and has been shown to reduce urinary osmolal-
ity in rats and produce a salt-sparing diuresis [23]. Motivated by the
DMTU ﬁndings, the study here was done to establish structure-activity
relationships of thiourea analogs for inhibition of UT-A1 and UT-B
urea transport, with the goal of identifying more potent and UT-A1-
selective analogs for use as research tools and as potential
development candidates. Our strategy, as diagrammed in Fig. 1,
was to initially screen symmetrical, close structural analogs of
DMTU, which was followed by screening of mono-N-substituted,
asymmetrical thioureas with greater structural diversity. Further
reﬁnement to improve potency was done by modiﬁcation of the
position and nature of substitutions. Compounds were identiﬁed
with N10-fold improved urea transport inhibition potency over
DMTU, as well as compounds with high UT-A1 or UT-B selectivity.
2. Material and methods
2.1. Compounds
Unless otherwise speciﬁed, urea/thiourea analogs were purchased
from Sigma-Aldrich (St. Louis, MO). Compounds 4, 26 and 27were pur-
chased from Acros Organics-Fisher Scientiﬁc (Pittsburgh, PA); 6 from
TCI (Portland, OR); 5, 9, 18, 21 and 25 from Alfa Aesar (Ward Hill,
MA); 10 and 28 from Santa Cruz Biotechnology (Dallas, TX) and 25
and 30 fromChemBridge (SanDiego, CA). Compound8was synthesized
as follows [24]: to a solution of N, N′-dimethylthiourea (200 mg,
DMTU 1
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Fig. 1. Strategy for identiﬁcation of thiourea analogs with improved potency.
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3.84 mmol) dropwise and the resulting mixture was reﬂuxed for 1 h
and then cooled to 0 °C. The resultingwhite solidwas dissolved in anhy-
drous methanol (5 mL) and reacted with freshly prepared NaSeH
(300mg, 2.88mmol) in ethanol (2mL) overnight. The reactionmixture
was neutralized with diluted acetic acid and the solvent was removed
under reduced pressure. The resulting mixture was diluted with
water, extracted with dichloromethane and the solution dried over
anhydrous sodium sulfate. The product was puriﬁed by crystallization
from dichloromethane solution and afforded 8 as a colorless solid
(98 mg, 34%). 1H NMR (chloroform-d) δ 6.60 (brs, 2H), 3.04 (brs, 6H);
13C NMR (chloroform-d) δ 180.2, 31.5. 1H and 13C NMR spectra were
obtained in chloroform (CDCl3) using a 300 MHz Varian spectrometer
referenced to TMS. Chemical shifts are expressed in units of Hertz
(Hz). Splitting pattern is designated as brs (broad singlet).
2.2. Cell culture
Madin–Darby canine kidney (MDCK) cells stably expressing rat
UT-A1, yellow ﬂuorescent protein (YFP)-H148Q/V163S and human
aquaporin-1 (AQP1), as described previously [19], were grown in
Dulbecco's modiﬁed Eagle medium (DMEM) containing 10% fetal
bovine serum, penicillin G (100 U/mL), streptomycin (100 μg/mL),
zeocin (500 μg/mL), geneticin (600 μg/mL) and hygromycin B (500
μg/mL) at 37 °C, 5% CO2.
2.3. UT-A1 inhibition assay
UT-A1 inhibition was measured as described [19]. The stably
transfected MDCK cells were plated in 96-well plates at a density of
15,000 cells/well at 37 °C for 24 h prior to assay. Brieﬂy, MDCK-
UT-A1-AQP1-YFP cells were incubated for 20 min with test com-
pounds and then subjected to an 800 mM urea gradient during
continuous measurement of the YFP ﬂuorescence with a plate reader
(model Inﬁnite M1000, Tecan Trading AG, Switzerland). The addi-
tion of urea to the triply transfected cells produces a rapid cell
shrinking (reduced ﬂuorescence) followed by UT-A1-facilitated cell
swelling (ﬂuorescence increase). UT-A1 inhibition increases the initial
ﬂuorescence decrease and slows recovery. Percentage UT-A1 inhibition
was computed as 100% (Fneg – Ftest) / (Fneg – Fpos), where F is the ﬂuores-
cencemeasured 7 s after urea addition of thenegative control (Fneg), test
compound (Ftest) and positive control (Fpos).
2.4. Functional studies
Reversibility of UT-A1 inhibition was tested by pre-incubation of
MDCK cellswith inhibitor at a concentration that inhibits urea transport
by ~50% and thenwashing the cells with PBS prior to assay. The kinetics
of UT-A1 inhibitionwasmeasured by adding inhibitor (at the same con-
centration used for the reversibility studies) at different times prior to
assay. The urea concentration-dependence of UT-A1 inhibition was
studied from inhibitor concentration-response data using different
urea gradients from 80 to 1600 mM.2.5. UT-B inhibition measurements
As described [20], whole rat blood was diluted to a hematocrit of
~1.5% in PBS containing 1.25 M acetamide and 5 mM glucose. Red
blood cell suspensions were added to microplates containing the test
compounds and incubated for 15 min. Cells were then subjected to a
rapid hypotonic gradient and their lysis was quantiﬁed by absorbance
at 710 nm. Phloretin was used as a positive control and percentage
erythrocyte lysis was computed as: % lysis = 100% (Aneg – Atest) /
(Aneg – Apos), where A is the absorbance for the negative control
(Aneg), test compound (Atest) and positive control (Apos) at 710 nm. In
some studies, urea permeability in rat erythrocytes was assayed by
stopped-ﬂow light scattering using a Hi-Tech Sf-51 instrument
(Wiltshire, UK) as described [20]. Brieﬂy, a 200-fold dilution of rat
blood cells in PBS was incubated with test compound for 10 min, and
then subjected to inwardly directed urea gradient (250-500 mM).
After an initial osmotic shrinking phase, the kinetics of increasing cell
volume caused by urea inﬂux was measured as the time course of 90°
scattered light intensity at 530 nm, with increasing cell volume
resulting in reduced scattered light intensity.
3. Results
Fig. 2A shows concentration-inhibition data for reference compound
DMTU, 1. UT-A1 inhibition was measured by a cell-based ﬂuorescence
assay in which cell volume, measured using an intracellular ﬂuorescent
indicator, is measured in response to extracellular DMTU addition (top,
left). UT-B inhibition was measured using an erythrocyte lysis assay
[20]. IC50 values for inhibition of UT-A1 and UT-B urea transport were
2–3 mMwith near complete inhibition seen at higher concentrations.
Symmetrical, bis-alkyl thiourea analogs with structural similarity to
DMTU were tested for UT-A1 and UT-B inhibition activity (Table 1).
Minor changes in the DMTU structure, such as replacing dimethyl
(DMTU, 1) with hydrogen (2) or diethyl (4), resulted in signiﬁcant
loss of UT-A1 and UT-B inhibition activity. Tetramethylthiourea 5,
which contains two additional methyl groups, and cyclic thioureas 6
and 7, were also inactive. Replacing the sulfur atom in DMTUwith oxy-
gen (dimethylurea 3) resulted in loss of activity, as did replacement
with selenium (dimethylselenourea 8). The loss of UT inhibition activity
in dimethylurea may be related to the signiﬁcant differences between
oxygen and sulfur in electronegativity (O = 3.5 Pauling unit, S = 2.5),
carbon–oxygen/sulfur bond length (C_O = 1.2 Å, C_S = 1.6 Å) and
van der Waals radius (O = 1.52 Å, S = 1.8 Å). The loss of inhibition
activity of 8 was unexpected, as sulfur and selenium have similar elec-
tronegativity (S = 2.5, Se = 2.4), and van der Waals radius (S =
1.8 Å, Se = 1.9 Å); however, the signiﬁcant difference in polarizability
of sulfur and selenium (S = 2.9 Å, Se = 3.8 Å) and slightly elongated
carbon-selenium bond length (C_S = 1.6 Å, C_Se = 1.86 Å) [25]
could account for its loss of activity.
As the symmetrical thiourea analogs examined above were not
active, we next tested a series of asymmetrical mono-substituted
thioureas. IC50 values are summarized in Table 2 and concentration–
inhibition data for selected compounds is shown in Fig. 2A. This
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Fig. 2.Urea transport inhibition by thiourea analogs. A. (top) UT-A1 concentration-inhibition curves for compounds 1 and 18 (bottom). Concentration-inhibition data for UT-A1 and UT-B
of thiourea analogs 1, 16, 18 and 26. B. Concentration–inhibition data for UT-A1 and UT-B of thiourea analogs 31, 32, 33, 35 and 36.
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urated cyclohexylthiourea 12, which each inhibited UT-A1 and UT-B
with potencies comparable to DMTU. Encouraged by these results,
we further tested phenyl rings with different steric and electronic
properties, including halide (13-15), electron-withdrawing
(16-18), electron-donating (19-20) and sterically crowded di- orTable 1
Structure-activity analysis of symmetrical DMTU analogs.
Inhibitor Structure
1
2
3
4
5
6
7
8tri-substitutions (21-24). Analogs with electron-withdrawing groups,
4-nitrophenylthiourea 18 and 3,4-dichlorophenylthiourea 21, gave the
best IC50 of 1.3 and 1.5 mM, respectively. Substitution at the 2-position
on the phenyl ring resulted in loss of activity as seen in thiourea analogs
22-24. Analogs with electron-donating groups, such as methoxy and
dimethylamino (19–20), were inactive. Also, an additional methyleneUT-A1 IC50 (mM) UT-B IC50 (mM)
6.6 ± 0.4 3.9 ± 0.6
N25 N25
22 ± 1 14 ± 2
N25 17 ± 2
N25 N25
N15 13 ± 2
N25 N25
N25 N25
Table 2
Structure-activity analysis of non-symmetrical DMTU analogs.
Inhibitor Structure R UT-A1 IC50
(mM)
UT-B IC50
(mM)
9 Aniline 8.8 ± 0.3 14 ± 1
10 2-Amino-benzimidazole 2.2 ± 0.3 4.7 ± 1.4
11 4-Amino-pyridine 5.3 ± 0.6 1.6 ± 0.3
12 4-Amino-cyclohexyl 3.7 ± 0.2 5.2 ± 0.6
13 4-Fluoro-aniline 13 ± 3 N15
14 4-Chloro-aniline 6.3 ± 1.3 N15
15 4-Bromo-aniline 3.8 ± 0.6 2.4 ± 0.2
16 4-Triﬂuoromethyl-aniline 15 ± 0.3 N15
17 4-Carboxy-aniline 7.5 ± 1.0 3.6 ± 0.6
18 4-Nitro-aniline 1.3 ± 0.3 10 ± 1
19 4-Methoxy-aniline N15 N15
20 4-Dimethylamino-aniline N15 N15
21 3,4-Dichloro-aniline 1.5 ± 0.4 0.4 ± 0.1
22 2,3-Dichloro-aniline N15 N15
23 2,6-Dichloro-aniline N15 N15
24 2,4,6-Trichloro-aniline 5.9 ± 1.1 N15
25 4-Chloro-benzylamine N15 N15
26 4-Pyridine N15 2.8 ± 0.5
27 3-Pyridine N25 10 ± 2
1078 C. Esteva-Font et al. / Biochimica et Biophysica Acta 1848 (2015) 1075–1080group between the amino group and phenyl ring resulted in loss of
activity (compare 14 and 25). Interestingly, thionicotinamide 26 and
thioisonicotinamide 27, which lack the second amino group found in
thiourea, were selective for UT-B over UT-A1.
Wenext focused on themost potent inhibitors, 4-nitrophenylthiourea
18 and 3,4-dichlorophenyl thiourea 21.N-phenyl and N-methyl substitu-
tion on 18 and 21, which gave thioureas 28-30, resulted in similar or
reduced potency (Table 3, data for selected compounds shown in
Fig. 2B). Changing the position of the nitro-group on phenylthioureaTable 3
Structure-activity analysis of nitrophenyl and chlorophenyl thiourea analogs.
Inhibitor Structure
28
29
30
31
32
33
34
35
36from para- to meta- (31) decreased activity while changing to ortho- (3-
nitrophenylthiourea 32) gave an IC50 of 0.2 mM for inhibition of both UT-
A1andUT-B, ~6-foldbetter than18.Wesought to further improve thepoten-
cy of 32 by N-substitution on the thiourea moiety, includingmethyl, phenyl,
3-nitrophenyl and semicarbazide groups (33-36). However, these substitu-
tions reduced inhibition activity for UT-A1 and UT-B.
Selectivity of the thiourea analogs for UT-A1 vs. UT-B inhibition is
summarized in Fig. 3A,which compares reciprocal IC50 values for inhibi-
tion of UT-A1 (abscissa) and UT-B (ordinate) urea transport. Several
compounds were UT-A1 selective (red squares), including 14, 18, 24
and 28, while 26 and 31 were UT-B selective (green triangles). The
most potent thioureas, 32 and 33, were non-selective.
Fig. 3B summarizes the structural determinants of compound poten-
cy and selectivity. Only thiourea analogs (X = S) were active, as urea
(X = O) and selenourea (X = Se) were inactive. Substitution at R1 in
thioureas with an aryl ring bearing electron-withdrawing substituents
such as 3,4-dichloro 4-nitro were most active, with 3-nitro giving the
best inhibition. In general, various cyclic rings at the R1 position, such
as pyridine, benzimidazole, cyclohexyl and substituted phenyls, also
gave good activity. Phenyl rings at R1 containing electron-donating
substituent resulted in loss of activity. For R2, unsubstitution (R2 = H)
gave the best inhibition, while increasing the size of the substituent
decreased activity (R2 = methyl, phenyl)
The most potent compound, 32, was further characterized. Fig. 4A
shows similar percentage of inhibition for UT-B and UT-A1, asmeasured
by stopped-ﬂow and plate reader assays, respectively. UT-A1 inhibition
by 32was fully reversible (Fig. 4B) and very rapid (Fig. 4C). The deduced
IC50 using a wide range of urea gradients (80 to 1600 mM) showed a
small increase in IC50 for both 32 and 33, suggesting a competitive inhi-
bitionmechanism (Fig. 4D). Thewater solubility of 32 and 33wasmea-
sured as 0.64 and 0.38mM, respectively, substantially lower than that ofUT-A1 IC50 (mM) UT-B IC50 (mM)
2.5 ± 0.5 N15
N15 N15
2.0 ± 0.6 2.3 ± 0.2
9.3 ± 0.7 4.8 ± 1.3
0.2 ± 0.1 0.2 ± 0.1
0.3 ± 0.2 0.3 ± 0.1
0.8 ± 0.2 4.4 ± 0.6
1.6 ± 0.9 1.1 ± 0.4
3.4 ± 0.7 3.4 ± 0.8
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cells at their solubility limit.4. Discussion
This study was done to identify more potent and selective thiourea
analogs than DMTU for inhibition of urea transporters. Minor symmetri-
cal modiﬁcations of DMTU resulted in loss of activity. We found that
some non-symmetrical substituted arylthiourea analogs gave better
inhibition activity than DMTU. Inhibition activity was dependent on
the stereo-electronic properties of the substituent, with electron-
withdrawing substituent at the meta-position on the aryl ring giving
greatest potency.
Two prior studies examined UT-B inhibition by small urea analogs. In
an early report,Mayrand and Levitt [26] studied inhibition of erythrocyte
urea transport by urea analogs using [14C] urea and a fast-ﬂow system.
UT-B inhibitionwas reported of various thiourea analogs at lowmillimo-
lar concentrations, including phenylthioureas or thionicotinamides, in
agreement with the data here. Zhao et al. [27] subsequently reported0.2
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for 15 min, then washed twice and subjected to UT-A1 inhibition assay. C. Kinetics of UT-A1
32. D. Concentration-inhibition data for 32 and 33 using 80 and 1600-mM urea gradients (leftthat various urea analogs permeate UT-B, albeit less well than urea itself,
and that some analogs were weak inhibitors of urea transport.
There are several prior reports on the pharmacological properties of
thioureas. DMTU is a hydroxyl radical scavenger that has been used in
animals to reduce cellular injury associatedwith production of hydroxyl
radicals. Pre-treatment of rats with DMTU (500 mg/kg) reduced
hyperoxia-induced lung edema [28], and DMTU given orally 30 min
prior to acute ethanol injury reduced stomach injury [29]. Pharmacolog-
ical data for other thioureas have also been reported. The ability to taste
the bitterness of phenylthiourea 9 (commonly known as phenylthiocar-
bamide) is a simple genetic trait governed by a pair of alleles, dominant
T for tasting and recessive t for non-tasting [30]. Interestingly, 9 has
been used to generate transparent zebraﬁsh by blocking tyrosinase-
dependent steps in the melanin pathway [31]. These reports suggest
that thioureas are well-tolerated, with minimal cytotoxicity in animals.
In general, thioureas are easily synthesized in 2-3 steps from commer-
cially available starting materials for further structure-activity analysis.
One of the reasons for investigating the inhibition potency and selec-
tivity of thiourea analogs was to improve on DMTU, which was shown
to have diuretic efﬁcacy in rats and hence potentially be used forUT-A1
UT-B
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1080 C. Esteva-Font et al. / Biochimica et Biophysica Acta 1848 (2015) 1075–1080proof-of-concept studies in clinically relevant models of edema. The
diuretic action of DMTU requires intraperitoneal injection at a very
high dose (500 mg/kg in saline) to reach stable levels above its IC50
(N3 mM) in plasma and urine [23]. In preliminary studies, we
investigated the potential use of 32 and 33 in rodents. Due to their
low water solubility compared to DMTU (soluble to N50 mg/mL in
saline) it was necessary to use a different delivery vehicle (5%
DMSO, 2.5% polyethylene glycol 400 and 2.4% Tween80 in saline; or
5% dimethylacetamide and 10% solutol or kolliphorHS15 in saline);
however, it was not possible to obtain plasma or urine concentra-
tions greater than 0.4 mM. Thus, though several thioureas identiﬁed
here had up to 10-fold improved UT inhibition potency compared to
DMTU, their low solubility precluded their use as UT inhibitors in
animal models.
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